2025年
Arai, K., Nishito, Y., Mizuno, H., Motoi, N., Hiraoka, N., Fuse, M., Arai, Y., Shibata, T., Sonobe, Y., Kayukawa, Y., Maruyama, T., Fukuda, H., Mizoguchi, Y., Aikawa, Y., Yoshida, Y., Watanabe, S. I., Sakamoto, H., Yamashita, M., Kitano, S., Nagata, Y., Mitsumori, R., Ozaki, K., Niida, S., Kanai, Y., Hirayama, A., Soga, T., Yoshida, T., Yasuda, K., Ochiai, A., Tsunoda, H., Aoki, K.
EML4-ALK rearrangement creates a distinctive myeloid cell-dominant immunosuppressive microenvironment in lung cancer.
Cancer Immunol. Res., in press, 2025
Fuji, S., Ohmoto, A.
Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis: current status and optimization strategies.
Curr. Opin. Immunol., 97 102662, 2025
Funasaka, C., Kogawa, T., Sakamoto, N., Kusuhara, S., Nakao, T., Nakajima, H., Kondoh, C., Harano, K., Matsubara, N., Hosono, A., Naito, Y., Shimokawa, M., Watanuki, R., Yamashita, Y., Yamauchi, C., Onishi, T., Ishii, G., Mukohara, T.
The utility of immunohistochemistry-based biomarkers in predicting the pathological complete response in early-stage triple-negative breast cancer.
Cancer Treat. Res. Commun., 44 100941, 2025
Hurvitz, S., Simonelli, M., Yarza, R., Berz, D., Kitano, S., Del Conte, G., Acosta Eyzaguirre, D., Doger de Speville Uribe, B. G., Maier, D., Erzen, D., Aykut Yazgili, S., Curigliano, G., Deng, T., Yan, M., Zhang, Q., Wang, X., Nakayama, I., Shitara, K.
Beamion BCGC-1: phase Ib/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancers.
Future Oncol., 1-9, 2025
Inamoto, Y., Ito, A., Nakashima, T., Usui, A., Takeda, W., Tanaka, T., Kim, S. W., Kitano, S., Watanabe, K., Kusaba, K., Aruga, Y., Ikeda, C., Kojima, M., Maezawa, N., Matsui, H., Hashimoto, H., Ogawa, C., Fukuda, T.
Oral beclomethasone dipropionate therapy and prognostic plasma biomarkers for gastrointestinal graft- versus-host disease.
Int. J. Hematol., 122 (2):257-266, 2025
Kitadai, R., Yazaki, S., Kuchiba, A., Yamanaka, T., Shiino, S., Yamauchi, C., Harano, K., Saito, M., Hirotsu, Y., Aiba, H., Yoshida, T., Hamamoto, R., Shimizu, C., Shimomura, A., Kojima, Y., Shimoi, T., Momozawa, Y., Sudo, K., Yoshida, M., Sunami, K., Hori, M., Katanoda, K., Shimada, Y., Yamashita, Y., Kogawa, T., Murata, T., Fujiwara, S., Miyagi, Y., Nakagomi, H., Tachibana, K., Omata, M., Ohtake, T., Suto, A., Onishi, T., Naito, Y., Yamashita, T., Yonemori, K., Kohno, T., Shiraishi, K.
Germline pathogenic variants and clinical outcomes in Asian patients with breast cancer.
Cancer Sci., 116 (4):1048-1058, 2025
Kondo, S., Kitano, S., Sato, J., Katsuya, Y., Kogawa, T., Mizugaki, H., Miyamoto, I., Iwasawa, S., Imaizumi, T., Tomita, H., Murakami, C., Miyake, T., Yamamoto, N.
An investigation of extended-interval dosing of atezolizumab in Japanese patients with advanced solid tumors: safety and pharmacokinetics of a dose of 1680 mg every 4 weeks.
Invest. New Drugs., 43 (3):602-608, 2025
Maeda, T., Ono, M., Osako, T., Chiba, T., Baba, S., Iesato, A., Ozaki, Y., Inoue, Y., Uehiro, N., Takahashi, Y., Kobayashi, T., Kogawa, T., Ohta, T., Kitano, S., Ueno, T., Ohno, S.
Prognostic impact of stimulator of interferon genes expression in triple negative breast cancer.
Cancer Med., 14 (4):e70666, 2025
Maruyama, S., Imamura, Y., Toihata, T., Haraguchi, I., Takamatsu, M., Yamashita, M., Nakashima, Y., Oki, E., Taguchi, K., Yamamoto, M., Mine, S., Okamura, A., Kanamori, J., Nunobe, S., Sano, T., Kitano, S., Noda, T., Watanabe, M.
FOXP3+/CD8+ ratio associated with aggressive behavior in RUNX3-methylated diffuse esophagogastric junction tumor.
Cancer Sci., 116 (1):178-191, 2025
Misawa, S., Denda, T., Kodama, S., Suzuki, T., Naito, Y., Kogawa, T., Takada, M., Hino, A., Shiosakai, K., Kuwabara, S.
One-year incidence of chemotherapy-induced peripheral neuropathy in oxaliplatin- or taxane-based chemotherapy: a multicenter, prospective registry study (MiroCIP study).
Expert Opin. Pharmacother., 26 (3):335-344, 2025
Misawa, S., Kogawa, T., Naito, Y., Suzuki, T., Takada, M., Denda, T., Hino, A., Suichi, T., Kodama, S., Miyoshi, A., Shiosakai, K., Kuwabara, S.
A subgroup analysis of the MiroCIP study to evaluate chemotherapy-induced peripheral neuropathy: symptom profile, severity, and analgesia efficacy depending on type of chemotherapy.
Expert Opin. Pharmacother., 26 (8):979-989, 2025
Mughees, M., Tacam, M. J., Tan, A. W., Pitner, M. K., Iles, L. R., Hu, X., E, S. V., Debeb, B. G., Kogawa, T., Lim, B., Layman, R. M., Woodward, W. A., Ueno, N. T., Tripathy, D., Krishnamurthy, S., Qi, Y., Pusztai, L., Wang, J., Gandhi, V., Bartholomeusz, G., Bartholomeusz, C.
Inhibition of MCL-1 and MEK overcomes MEK inhibitor resistance in triple-negative and inflammatory breast cancers.
Mol. Cancer Ther., in press, 2025
Ohmoto, A., Yamada, Y., Fuji, S.
Transplant-acquired allergy in HCT-recipients: Reference for clinical management.
Blood Rev., 101289, 2025
Ohmoto, A., Fuji, S.
Alternative regimen for chemotherapy-intolerant lymphoma including practical aspects in Japan.
Expert Rev. Anticancer Ther., 25 (5):423-433, 2025
Seki, H., Watanabe, N., Nagura, N., Ogiya, A., Shimo, A., Uehiro, N., Tsuji, W., Tomita, S., Tsukioki, T., Isaka, H., Shiraishi, T., Nishida, Y., Yamauchi, C., Sasada, S.
Impact of radiation therapy on breast satisfaction and health-related quality of life after breast reconstruction: a multicenter cross-sectional controlled study (Reborn study-02).
Breast Cancer, in press, 2025
Ono, M., Nagasaki, R., Nakamura, M., Hamaguchi, K., Yokoi, M., Matsuura, N., Utsugi, K., Kataoka, A., Takano, T., Watanabe, M.
Appearance-related needs and challenges among cancer patients undergoing systemic therapy: a comprehensive survey study.
Int. J. Clin. Oncol., 30 (3):469-479, 2025
Osumi, H., Wakatsuki, T., Ooki, A., Chin, K., Shoji, H., Ogura, M., Nakayama, I., Yamamoto, N., Hirano, H., Hara, H., Minashi, K., Shinozaki, E., Kato, K., Ishizuka, N., Kitano, S., Takeuchi, K., Boku, N., Yamaguchi, K., Takahari, D.
Clinical relevance of circulating tumor DNA in HER2-positive advanced gastric cancer: a collaborative study of a phase Ib trial of dual HER2 and PD-1 targeted therapy (Ni-High).
Ther. Adv. Med. Oncol., 17 17588359251367344, 2025
Powles, T., Bhatia, A., Burtness, B., Kogawa, T., Nishina, T., Nakayama, I., Fountzilas, C., Castillo, D. R., McKean, M., Meric-Bernstam, F., Colombo, N., Smithy, J. W., Fayette, J., Chandra, S., Sternberg, D. W., Jin, F., Sullivan, K., Yueh, S., Clinthorne, G., Aguilo, A. E., Kudchadkar, R., Hayashi, H. HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors.
Future Oncol., 21 (25):3283-3292, 2025
Shimamura, S. S., Shukuya, T., Yamashita, M., Ikarashi, D., Hayashi, T., Ohtsu, H., Xu, S., Kanamori, K., Matsunaga, T., Fukui, M., Hattori, A., Takamochi, K., Suzuki, K., Kitano, S., Takahashi, K.
Comparative analysis of the tumor immune microenvironment between thymoma and thymic carcinoma. Lung Cancer, 209 108785, 2025
Yanai, Y., Mikami, S., Yasumizu, Y., Takeda, T., Matsumoto, K., Kitano, S., Oya, M., Kosaka, T.
Loss of phosphatase and tensin homolog expression castration-sensitive prostate cancer predicts outcomes in men after prostatectomy.
Int. J. Urol., 32 (1):39-44, 2025
Yanai, Y., Kosaka, T., Mikami, S., Arai, M., Watanabe, K., Takeda, T., Matsumoto, K., Yamashita, M., Kitano, S., Oya, M.
Dynamics in the prostate immune microenvironment induced by androgen deprivation therapy.
Prostate, 85 (3):308-314, 2025
Yazaki, S., Hori, M., Aiba, H., Momozawa, Y., Yoshida, M., Shiino, S., Harano, K., Yamauchi, C., Yamanaka, T., Miwa, M., Matsuda, K., Kawai, Y., Kobayashi-Kato, M., Kitagawa, M., Saito, M., Nakagomi, H., Tachibana, K., Sakamoto, I., Takahashi, K., Asami, Y., Katanoda, K., Kuchiba, A., Yoshida, H., Ishikawa, M., Shimoi, T., Sudo, K., Shimizu, C., Shimomura, A., Murata, T., Yamashita, Y., Kogawa, T., Fujiwara, S., Saji, H., Kato, H., Miyagi, E., Iwasaki, Y., Aoi, T., Takata, S., Ogasawara, A., Ohtake, T., Fujimori, K., Hirotsu, Y., Nagashima, M., Komatsu, M., Hamamoto, R., Hirata, M., Yoshida, T., Honda, T., Hiranuma, K., Matsuda, M., Shimada, Y., Sunami, K., Noiri, E., Omae, Y., Matsumoto, K., Okamoto, A., Omata, M., Watanabe, T., Miyagi, Y., Murakami, Y., Tokunaga, K., Hasegawa, K., Kato, T., Onishi, T., Yamashita, T., Naito, Y., Suto, A., Yonemori, K., Kohno, T., Shiraisihi, K.
Impact of germline variants on breast and ovarian cancer risk in Japanese women: an original cohort study and meta-analysis.
EBioMedicine, 116 105758, 2025
Yonemori, K., Shimoi, T., Yamamoto, K., Kogawa, T., Kitano, S., Kobayashi, S., Yanai, K., Yamaguchi, K., Otake, Y., Hojo, S., Ono, M.
Phase I study of H3B-6545 in patients with estrogen receptor-positive breast cancer.
ESMO Open, 10 (6):105290, 2025
2024年
Abe, T., Kataoka, A., Uehiro, N., Yoshida, N., Nishimura, M., Ozaki, Y., Kogawa, T., Takano, T., Ohno, S., Ueno, T.
Desire for pregnancy and fertility preservation in young patients with breast cancer.
Breast Cancer, 31 (6):1137-1143, 2024
Hattori, M., Honma, N., Nagai, S., Narui, K., Shigechi, T., Ozaki, Y., Yoshida, M., Sakatani, T., Sasaki, E., Tanabe, Y., Tsurutani, J., Takano, T., Saji, S., Masuda, S., Horii, R., Tsuda, H., Yamaguchi, R., Toyama, T., Yamauchi, C., Toi, M., Yamamoto, Y.
Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: Recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines.
Breast Cancer, 31 (3):335-339, 2024
Bardia, A., Krop, I. E., Kogawa, T., Juric, D., Tolcher, A. W., Hamilton, E. P., Mukohara, T., Lisberg, A., Shimizu, T., Spira, A. I., Tsurutani, J., Damodaran, S., Papadopoulos, K. P., Greenberg, J., Kobayashi, F., Zebger-Gong, H., Wong, R., Kawasaki, Y., Nakamura, T., Meric-Bernstam, F.
Datopotamab deruxtecan in advanced or metastatic HR+/HER2- and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study.
J. Clin. Oncol., 42 (19):2281-2294, 2024
Hayashi, N., Mori, S., Ohmoto, A., Fukada, I., Yamazaki, M., Hosonaga, M., Wang, X., Ueki, A., Kiyotani, K., Tonooka, A., Takeuchi, K., Takahashi, S.
Availability of genome-matched therapy based on clinical practice.
Int. J. Clin. Oncol., 29 (7):964-971, 2024
Heist, R. S., Sands, J., Bardia, A., Shimizu, T., Lisberg, A., Krop, I., Yamamoto, N., Kogawa, T., Al-Hashimi, S., Fung, S. S. M., Galor, A., Pisetzky, F., Basak, P., Lau, C., Meric-Bernstam, F.
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan.
Cancer Treat. Rev., 125 102720, 2024
Ikezawa, Y., Morita, R., Mizugaki, H., Tateishi, K., Yokoo, K., Sumi, T., Kikuchi, H., Kitamura, Y., Nakamura, A., Kobayashi, M., Aso, M., Kimura, N., Yoshiike, F., Megumi, F., Tanaka, H., Sekikawa, M., Hachiya, T., Nakamura, K., Hommura, F., Sukoh, N., Ito, K., Kikuchi, T., Agatsuma, T., Yokouchi, H.
Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: updated analysis.
Cancer Med., 13 (14):e70036, 2024
Nagatani, Y., Kiyota, N., Imamura, Y., Koyama, T., Funakoshi, Y., Komatsu, M., Itoh, T., Teshima, M., Nibu, K. I., Sakai, K., Nishio, K., Shimomura, M., Nakatsura, T., Ikarashi, D., Nakayama, T., Kitano, S., Minami, H.
Different characteristics of the tumor immune microenvironment among subtypes of salivary gland cancer. Asia Pac. J. Clin. Oncol., 20 (6):779-788, 2024
Naito, Y., Nakamura, S., Kawaguchi-Sakita, N., Ishida, T., Nakayama, T., Yamamoto, Y., Masuda, N., Matsumoto, K., Kogawa, T., Sudo, K., Shimomura, A., Lai, C., Zhang, D., Iwahori, Y., Gary, D., Huynh, D., Iwata, H.
Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors.
Int. J. Clin. Oncol., 29 (11):1684-1695, 2024
Park, K. H., Loibl, S., Sohn, J., Park, Y. H., Jiang, Z., Tadjoedin, H., Nag, S., Saji, S., Md Yusof, M., Villegas, E. M. B., Lim, E. H., Lu, Y. S., Ithimakin, S., Tseng, L. M., Dejthevaporn, T., Chen, T. W., Lee, S. C., Galvez, C., Malwinder, S., Kogawa, T., Bajpai, J., Brahma, B., Wang, S., Curigliano, G., Yoshino, T., Kim, S. B., Pentheroudakis, G., Im, S. A., Andre, F., Ahn, J. B., Harbeck, N.
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer.
ESMO Open, 9 (5):102974, 2024
Patel, M. R., Johnson, M., Winer, I., Arkenau, H. T., Cook, N., Samouëlian, V., Aljumaily, R., Kitano, S., Duffy, C., Ge, M., Elgadi, M., Siu, L. L.
Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours.
Cancer Immunol. Immunother., 73 (5):89, 2024
Shien, T., Tsuda, H., Sasaki, K., Mizusawa, J., Akiyama, F., Kurosumi, M., Sawaki, M., Tamura, N., Tanaka, K., Kogawa, T., Takahashi, M., Hayashi, N., Mukai, H., Masuda, N., Hara, F., Iwata, H.
Comparison of proportions and prognostic impact of pathological complete response between evaluations of representative specimen and total specimen in primary breast cancer after neoadjuvant chemoradiotherapy: an ancillary study of JCOG0306.
Breast Cancer Res. Treat., 208 (1):145-154, 2024
Xie, X., Chauhan, G. B., Edupuganti, R., Kogawa, T., Park, J., Tacam, M., Tan, A. W., Mughees, M., Vidhu, F., Liu, D. D., Taliaferro, J. M., Pitner, M. K., Browning, L. S., Lee, J. H., Bertucci, F., Shen, Y., Wang, J., Ueno, N. T., Krishnamurthy, S., Hortobagyi, G. N., Tripathy, D., Van Laere, S. J., Bartholomeusz, G., Dalby, K. N., Bartholomeusz, C.
Correction: Maternal embryonic leucine zipper kinase is associated with metastasis in triple-negative breast cancer.
Cancer Res. Commun., 4 (1):236, 2024
Xu, S., Shukuya, T., Shimamura, S., Hayashi, T., Sato, Y., Shiozaki, H., Nishioki, T., Nishino, K., Kato, M., Hattori, A., Shimada, N., Suzuki, K., Kitano, S., Takahashi, K.
Hyperprogressive disease under anti-PD-1 rechallenge after initial response to anti-PD-1 treatment for non- small cell lung cancer: a case report.
Transl. Lung Cancer Res., 13 (3):666-672, 2024
Yamamoto, N., Kitano, S., Koyama, T., Ikeda, M., Mizugaki, H., Narikiyo, T., Yamaguchi, Y., Ishida, T., Takubo, R., Ogami, C., Sekiya, M., Nakagawa, Y., Kuboki, Y.
Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers.
J. Immunother. Cancer, 12 (7):e009262, 2024
2023年
Fukada, I., Mori, S., Hayashi, N., Hosonaga, M., Xiaofei, W., Yamazaki, M., Ueki, A., Kiyotani, K., Tonooka, A., Takeuchi, K., Ueno, T., Takahashi, S.
Prognostic impact of cancer genomic profile testing for advanced or metastatic solid tumors in clinical practice.
Cancer Sci., 114 (12):4632-4642, 2023
Funasaka, C., Hanai, A., Zenda, S., Mori, K., Fukui, M., Hirano, N., Shinohara, R., Fuse, N., Wakabayashi, M., Itagaki, M., Tomioka, Y., Nishina, M., Arai, Y., Kogawa, T., Ozaki, Y., Nishimura, M., Kobayashi, T., Hara, F., Takano, T., Mukohara, T.
Mitigation of paclitaxel-induced peripheral neuropathy in breast cancer patients using limb-cooling apparatus: A study protocol for a randomized controlled trial.
Front. Oncol., 13 1216813, 2023
Misawa, S., Denda, T., Kodama, S., Suzuki, T., Naito, Y., Kogawa, T., Takada, M., Suichi, T., Shiosakai, K., Kuwabara, S.
Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single- arm trial (MiroCIP study).
BMC Cancer, 23 (1):1098, 2023
Nishizawa, A., Takeda, K., Urasaki, T., Ono, M., Mochizuki, T., Shiga, T., Fujiwara, M., Yuasa, T., Murakami, A., Koike, R., Yunokawa, M., Kanao, H., Shimozaki, K., Takahari, D., Kogawa, T., Takahashi, S., Kitano, S.
Severe drug eruption after antibiotic administration in patients receiving immune checkpoint inhibitors: A monocentric case series.
JEADV Clin. Pract., 2 (2):330-337, 2023
Omori, S., Muramatsu, K., Kawata, T., Miyawaki, E., Miyawaki, T., Mamesaya, N., Kawamura, T., Kobayashi, H., Nakashima, K., Wakuda, K., Ono, A., Kenmotsu, H., Naito, T., Murakami, H., Sugino, T., Takahashi, T.
Immunohistochemical analysis of B7-H3 expression in patients with lung cancer following various anti- cancer treatments.
Invest. New Drugs., 41 (2):356-364, 2023
Ozaki, Y., Masuda, J., Kataoka, A., Kogawa, T., Abe, T., Morizono, H., Inagaki, R., Hara, F., Takano, T., Ueno, T., Ohno, S.
The impact of obesity and endocrine therapy on the prognosis of premenopausal women with hormone receptor-positive breast cancer: A single-institute retrospective study.
Cancer Rep., 6 (2):e1695, 2023
2022年
Fukumitsu, M., Ariyasu, R., Ishiyama, M., Mochizuki, T., Takeda, K., Ono, M., Oyakawa, T., Ebina, A., Nishizawa, A., Tomomatsu, J., Kogawa, T., Kitano, S., Shiga, T.
Myocarditis associated with immune-checkpoint inhibitors diagnosed by cardiac magnetic resonance imaging.
Int. Cancer Conf. J., 12 (2):109-114, 2022
Masuda, N., Ono, M., Mukohara, T., Yasojima, H., Shimoi, T., Kobayashi, K., Harano, K., Mizutani, M., Tanioka, M., Takahashi, S., Kogawa, T., Suzuki, T., Okumura, S., Takase, T., Nagai, R., Semba, T., Zhao, Z. M., Ren, M., Yonemori, K.
Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort.
Eur. J. Cancer, 168 108-118, 2022
Niguma, K., Mamishin, K., Naito, Y., Nomura, S., Wakabayashi, M., Kusuhara, S., Funasaka, C., Nakao, T., Fukasawa, Y., Kondoh, C., Harano, K., Kogawa, T., Matsubara, N., Hosono, A., Onishi, T., Kawasaki, T., Mukohara, T.
Impact of Older Age and Medico-social Factors on the Decision to Offer Adjuvant Chemotherapy to Patients With Breast Cancer.
Anticancer Res., 42 (7):3743-3751, 2022
2021年
Doi, T., Fujiwara, Y., Shitara, K., Shimizu, T., Yonemori, K., Matsubara, N., Ohno, I., Kogawa, T., Naito, Y., Leopold, L., Munteanu, M., Yatsuzuka, N., Han, S. R., Samkari, A., Yamamoto, N.
The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434).
Invest. New Drugs., 39 (1):152-162, 2021
Funasaka, C., Naito, Y., Kusuhara, S., Nakao, T., Fukasawa, Y., Mamishin, K., Komuro, A., Okunaka, M., Kondoh, C., Harano, K., Kogawa, T., Matsubara, N., Hosono, A., Kawasaki, T., Mukohara, T.
The efficacy and safety of paclitaxel plus bevacizumab therapy in breast cancer patients with visceral crisis. Breast, 58 50-56, 2021
Hasegawa, Y., Matsubara, N., Kogawa, T., Naito, Y., Harano, K., Hosono, A., Onishi, T., Hojo, T., Shimokawa, M., Mukohara, T.
Neo-bioscore in guiding post-surgical therapy in patients with triple-negative breast cancer who received neoadjuvant chemotherapy.
In Vivo, 35 (2):1041-1049, 2021
Kai, M., Marx, A. N., Liu, D. D., Shen, Y., Gao, H., Reuben, J. M., Whitman, G., Krishnamurthy, S., Ross, M. I., Litton, J. K., Lim, B., Ibrahim, N., Kogawa, T., Ueno, N. T.
A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer.
Sci. Rep., 11 (1):22242, 2021
Kogawa, T., Sato, Y., Shimoyama, R., Kurata, W., Tashiro, Y., Niitsu, Y.
Chemoprevention of pancreatic cancer by inhibition of glutathione-S transferase P1.
Invest. New Drugs., 39 (6):1484-1492, 2021
Mamishin, K., Naito, Y., Nomura, S., Ogawa, G., Niguma, K., Baba, K., Sakaeda, S., Nakajima, H., Kusuhara, S., Funasaka, C., Nakao, T., Fukasawa, Y., Kondoh, C., Harano, K., Kogawa, T., Matsubara, N., Hosono, A., Kawasaki, T., Mukohara, T.
Comparison of treatment completion rate between conventional and dose-dense doxorubicin and cyclophosphamide (AC) followed by a taxane in patients with breast cancer: A propensity score-matched analysis.
Anticancer Res., 41 (12):6217-6224, 2021
Naito, Y., Kuboki, Y., Ikeda, M., Harano, K., Matsubara, N., Toyoizumi, S., Mori, Y., Hori, N., Nagasawa, T., Kogawa, T.
Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study.
Invest. New Drugs., 39 (6):1568-1576, 2021
Sagara, Y., Mori, M., Yamamoto, S., Eguchi, K., Iwatani, T., Naito, Y., Kogawa, T., Tanaka, K., Kotani, H., Yasojima, H., Ozaki, Y., Noguchi, E., Miyasita, M., Kondo, N., Niikura, N., Toi, M., Shien, T., Iwata, H. Current status of advance care planning and end-of-life communication for patients with advanced and metastatic breast cancer.
Oncologist, 26 (4):e686-e693, 2021
Shimokawa, M., Hayashi, T., Nishimura, J., Satoh, T., Fukunaga, M., Matsui, R., Tsuji, Y., Mizuki, F., Kogawa, T.
Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk.
BMC Cancer, 21 (1):1111, 2021
Takeda, K., Nakano, K., Udagawa, S., Fukuda, N., Nishizawa, A., Ono, M., Urasaki, T., Tomomatsu, J., Mochizuki, T., Shiga, T., Kogawa, T., Takahashi, S., Kitano, S.
Chilblain lupus-like cutaneous reaction associated with systemic lupus erythematosus induced by immune checkpoint inhibitor.
Rheumatology (Oxford), 61 (1):e13-e14, 2021
2020年
Kogawa, T., Fujii, T., Wu, J., Harano, K., Fouad, T. M., Liu, D. D., Shen, Y., Masuda, H., Krishnamurthy, S., Chavez-MacGregor, M., Lim, B., Murthy, R. K., Valero, V., Tripathy, D., Ueno, N. T.
Prognostic value of HER2 to CEP17 ratio on fluorescence in situ hybridization ratio in patients with nonmetastatic HER2-positive inflammatory and noninflammatory breast cancer treated with neoadjuvant chemotherapy with or without trastuzumab.
Oncologist, 25 (6):e909-e919, 2020
Masuda, T., Noda, M., Kogawa, T., Kitagawa, D., Hayashi, N., Jomori, T., Nakanishi, Y., Nakayama, K. I., Ohno, S., Mimori, K.
Phase I dose-escalation trial to repurpose propagermanium, an oral CCL2 inhibitor, in patients with breast cancer.
Cancer Sci., 111 (3):924-931, 2020
Sasaki, A., Harano, K., Kogawa, T., Matsubara, N., Naito, Y., Hosono, A., Mukai, H., Yoshino, T., Mukohara, T.
Intestinal perforation due to neutropenic enterocolitis in a patient treated with bevacizumab for ovarian cancer.
Case Rep. Oncol. Med., 2020 7231358, 2020
Shingaki, S., Kogawa, T., Shimokawa, M., Harano, K., Naito, Y., Kusuhara, S., Fujimoto, Y., Matsubara, N., Hosono, A., Mukai, H., Onishi, T., Hojo, T., Mukohara, T.
Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer. J. Cancer, 11 (14):4099-4105, 2020
Yamashita, S., Hattori, N., Fujii, S., Yamaguchi, T., Takahashi, M., Hozumi, Y., Kogawa, T., El-Omar, O., Liu, Y. Y., Arai, N., Mori, A., Higashimoto, H., Ushijima, T., Mukai, H.
Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy.
Sci. Rep., 10 (1):15530, 2020